Table 1 Demographics and characteristics of the plasma donor cohort.

From: Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy

Patient characteristics Samples, n (%) Individuals, n (%)
Sex
  Female 213 (39.4) 88 (50.3)
  Male 327 (60.6) 87 (49.7)
Age
  20–30 95 (17.6) 26 (14.9)
  31–40 117 (21.7) 39 (22.3)
  41–50 166 (30.7) 51 (29.1)
  51–60 117 (21.7) 40 (22.9)
  >60 45 (8.3) 19 (10.9)
Average (95% CI) 43.8 (42.7–44.9) 44.9 (43.0–46.8)
Median (IQR) 44 (33–53) 46 (36–54)
Range 20–78 20–78
Severity
  1 244 (45.2) 76 (43.4)
  2 182 (33.7) 63 (36.0)
  3 23 (4.3) 10 (5.7)
  4 44 (8.1) 15 (8.6)
  5 47 (8.7) 11 (6.3)
Median (IQR) 2 (1–2) 2 (1–2)
Range 1–5 1–5
Dyspnea
  No 250 (46.3) 79 (45.1)
  Yes 290 (53.7) 96 (54.9)
DPO
  <31 39 (7.2) 35 (20.0)
  31–60 181 (33.5) 89 (50.9)
  61–90 173 (32.0) 44 (25.1)
  91–120 122 (22.6) 7 (4.0)
  >120 25 (4.6)
Average (95% CI) 70.8 (68.4–73.3) 49.5 (46.5–52.5)
Median (IQR) 68 (48–93) 46 (32–63)
Range 17–142 17–108
Hospitalization
  No 428 (79.3) 141 (80.6)
  Yes 112 (20.7) 34 (19.4)
Total 540 175
  1. Study cohort characteristics such as sex, age, disease severity, dyspnea, and hospitalization records are provided.